Prime Medicine doses first patient in Phase 1/2 trial of PM577a for H1069Q-mutated Wilson disease
Bitget2026/10/05 12:13Prime Medicine dosed the first patient in a global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson disease. The first-in-human study aims to assess safety and early signs of benefit from a one-time gene-editing treatment. Initial clinical data are expected in 2027, with results to be presented in the future. The FDA granted Rare Pediatric Disease designation to PM577, supporting the program’s regulatory strategy in a childhood-onset condition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800PRIMZONEFULLFEED9839217) on October 05, 2026, and is solely responsible for the information contained therein.
- Prime Medicine dosed the first patient in a global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson disease.
- The first-in-human study aims to assess safety and early signs of benefit from a one-time gene-editing treatment.
- Initial clinical data are expected in 2027, with results to be presented in the future.
- The FDA granted Rare Pediatric Disease designation to PM577, supporting the program’s regulatory strategy in a childhood-onset condition.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Crypto prices
More
